In this study, the macrophage phagocytosis of tumor cells was restored after treatment with CD47 antibodies [131], and the macrophage-mediated phagocytosis was further enhanced in the presence of chemotherapeutic drugs, suggesting that patients with lower CD47 expression were more likely to benefit from adjuvant TACE treatment. The gene discussed is CD47; the disease is neoplasm.